Stool test could replace endoscopy for h. pylori treatment decisions
NCT ID NCT05495854
First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times
Summary
This study tested whether a simple stool test can guide doctors in choosing the right antibiotics for H. pylori infections, avoiding the need for an invasive stomach camera procedure. The test detects the bacteria and checks for antibiotic resistance, aiming to improve cure rates. The study involved 246 adults in primary care and measured success with a breath test six weeks after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
245 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Person over 18 years old * Patient affiliated or beneficiary of a social security scheme. * Informed consent signed by the patient after clear and fair information about the study * Patient registered on the list of patients who signed a doctor's statement with the investigating doctor. * Patient with an indication for research and treatment of an Hp infection according to National Health Authority (HAS) recommendations: 1. Suffering from (at least one) : Chronic dyspepsia; Iron deficiency anemia without a found cause or resistant to iron supplementation; Vitamin B12 deficiency without a found cause; familial gastric cancer DCDS; Immunological thrombocytopenic purpura in adulthood; history of peptic ulcers or precancerous lesions that have not been eradicated; Long-term consumption of NSAIDs; Long-term PPI consumption. or 2. Patient who received Hp eradication treatment without eradication control. or 3. Patient with risk factors for gastric cancer: person related to a patient who has had stomach cancer (parents, brothers / sisters, children). or 4. Patient with a syndrome of predisposition to digestive cancers (Hereditary non-polyposis colorectal carcinoma cancer HNPCC / Lynch syndrome). or 5. Patient who has had a partial gastrectomy or endoscopic treatment of gastric cancerous lesions. or 6. Patient with pre-neoplastic gastric lesions (severe atrophy and / or intestinal metaplasia, dysplasia). or 7. Patient who has already undergone an endoscopy with detection of Hp but without antibiotic sensitivity test (biopsy not addressed in bacteriology) and for whom we want to undergo a guided treatment. Exclusion Criteria: * Patient benefiting from enhanced protection, namely minors, pregnant or breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection and finally patients in emergency situations. * Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal / mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy). Exclusion criteria related to non-compliance with ambivalence: * Allergy to amoxicillin (suspected or documented). * Contraindication to eso-gastro-duodenal fibroscopy and biopsies. * Use of antibiotic within 15 days before enrolment. * Patient with an indication to perform an endoscopy of the upper digestive system in Emergency according to the criteria of "the European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE II)": upper gastrointestinal hemorrhage; acute deglobulization without digestive hemorrhage externalized; ingestion of caustics; acute dysphagia or ingestion of foreign bodies. * Participating another interventional trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ANDRIEUX Marine
Vaux-sur-Mer, France
-
ARCHAMBAULT Pierrick
Nueil-les-Aubiers, France
-
Christophe BONNET
Tonnay-Charente, France
-
Claude SAPIN
La Roche-Posay, France
-
Elodie POUPIN
Saint-Germain-de-Marencennes, France
-
FRECHE Bernard
Vaux-sur-Mer, France
-
Gwenaelle FARCY
La Mothe-Saint-Héray, France
-
Lise BLANCHARD
Mignaloux-Beauvoir, France
-
Marc CHABANNE
Pont Labbe Darnoult, France
-
Marie ROCHEPEAU
La Mothe-Saint-Héray, France
-
Vincent HELIS
Frontenay-Rohan-Rohan, France
-
Vincent JEDAT
Saint-Jean-d'Angély, France
-
philippe BRAVIN
Jarnac-Champagne, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heartburn drug under the microscope: registry tracks thousands of pregnancies
- Can probiotics make h. pylori antibiotics easier on the gut?
- Can a common seed oil boost stomach infection treatment?
- Two antibiotic cocktails face off to wipe out stomach bacteria
- Could a routine blood count reveal hidden stomach infection?
- A simple breath test after a heart attack could prevent dangerous bleeding